Financial Performance - Operating revenue for Q1 2024 was CNY 23,522,483.19, down 21.19% from CNY 29,845,357.86 in Q1 2023[10] - Net profit attributable to shareholders for Q1 2024 was CNY 1,162,697.87, a decline of 65.29% compared to CNY 3,349,806.12 in the same period last year[10] - Total operating revenue for Q1 2024 was CNY 23,522,483.19, a decrease of 21.2% compared to CNY 29,845,357.86 in Q1 2023[37] - Net profit for Q1 2024 was CNY 1,162,697.87, a decline of 65.3% from CNY 3,349,806.12 in Q1 2023[38] - The total comprehensive income amounted to CNY 1,816,490.67 for Q1 2024, compared to CNY 3,847,782.90 in Q1 2023, indicating a significant decrease[40] Cash Flow - The company reported a net cash flow from operating activities of -CNY 17,116,520.47, a decrease of 29.12% from -CNY 13,256,463.90 in the previous year[10] - Cash inflows from operating activities were CNY 8,685,409.83 in Q1 2024, down from CNY 18,434,424.30 in Q1 2023, reflecting a decline of approximately 53%[42] - The net cash flow from operating activities was negative CNY 17,116,520.47 in Q1 2024, worsening from negative CNY 13,256,463.90 in Q1 2023[43] - Cash outflows for operating activities totaled CNY 25,801,930.30 in Q1 2024, compared to CNY 31,690,888.20 in Q1 2023, a decrease of about 18%[43] - The net cash flow from investing activities was negative CNY 50,280,640.85 in Q1 2024, compared to negative CNY 24,262,448.98 in Q1 2023, indicating increased investment outflows[43] - The company experienced a significant increase in cash outflows related to investment activities, totaling CNY 100,519,442.21 in Q1 2024, compared to CNY 68,465,752.65 in Q1 2023[43] Assets and Liabilities - Total assets as of March 31, 2024, were CNY 261,390,690.45, a decrease of 2.17% compared to the end of 2023[10] - Cash and cash equivalents decreased by 62.48% to CNY 40,513,208.51 due to investments in financial products[11] - Accounts receivable increased by 408.64% to CNY 17,526,435.90, primarily due to changes in dealer payment terms[11] - Total liabilities decreased to CNY 66,226,596.76 from CNY 72,993,083.14[36] - Total assets amounted to ¥261,390,690.45, a decrease from ¥267,175,312.10 as of December 31, 2023, reflecting a decline of approximately 2.94%[31] Shareholder Information - The total number of ordinary shares at the end of the period was 43,333,100, with 25.35% being unrestricted shares[19] - The largest shareholder, Lv Mingjie, holds 26,143,000 shares, representing 60.33% of the total shares[21] - The company has 1,757 ordinary shareholders, indicating a stable shareholder base[20] - The annual profit distribution plan for 2023 was disclosed on March 15, 2024, indicating ongoing shareholder engagement[28] Legal and Regulatory Matters - There were no significant legal disputes or external guarantees reported during the period[25] - The company has not undergone any asset seizures or investigations during the reporting period[25] - No new commitments were made during the reporting period, maintaining previously disclosed commitments[28] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders was 0.60% for Q1 2024, down from 2.65% in Q1 2023[10] - Research and development expenses for Q1 2024 were CNY 1,584,468.00, slightly down from CNY 1,718,947.40 in Q1 2023[37] - Investment income for Q1 2024 was CNY 334,134.69, up from CNY 203,303.67 in Q1 2023[38] - The company reported a credit impairment loss of CNY -755,678.04 in Q1 2024, an improvement from CNY -984,807.25 in Q1 2023[38]
博迅生物(836504) - 2024 Q1 - 季度财报